Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
| العنوان: | Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs |
|---|---|
| المؤلفون: | Matthew J L Munro, Stanley L. Marks, Chen Gilor, Sean E. Hulsebosch |
| المصدر: | Journal of Veterinary Internal Medicine, Vol 35, Iss 4, Pp 1733-1742 (2021) Journal of Veterinary Internal Medicine Journal of veterinary internal medicine, vol 35, iss 4 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Veterinary medicine, Standard Article, 030204 cardiovascular system & hematology, Cardiovascular, Gastroenterology, 0403 veterinary science, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Fenofibrate, Hyperlipidemia, SF600-1100, Medicine, Dog Diseases, Prospective Studies, Hypolipidemic Agents, medicine.diagnostic_test, hypercholesterolemia, nephrotic syndrome, creatinine, Complete blood count, 04 agricultural and veterinary sciences, Standard Articles, 6.1 Pharmaceuticals, medicine.drug, medicine.medical_specialty, 040301 veterinary sciences, hypertriglyceridemia, Hyperlipidemias, 03 medical and health sciences, Dogs, lipemia, Internal medicine, Animals, Veterinary Sciences, Adverse effect, Creatinine, General Veterinary, Triglyceride, business.industry, creatine kinase, Hypertriglyceridemia, Evaluation of treatments and therapeutic interventions, medicine.disease, chemistry, Nanoparticles, SMALL ANIMAL, business, Nephrotic syndrome |
| الوصف: | BackgroundSafe, effective, and readily available drug therapies are required for the management of hyperlipidemia and its associated complications in dogs.ObjectivesTo investigate the efficacy of a micronized, nanocrystal formulation of fenofibrate (Tricor) in the treatment of hyperlipidemia in dogs.AnimalsTen client-owned dogs with primary (n=7) and secondary (n=3) hyperlipidemia. All dogs had hypertriglyceridemia at baseline; 3 dogs also had hypercholesterolemia.MethodsProspective dose-escalation study. Dogs were treated with fenofibrate orally once daily in up to 3cycles of 21 days each. Fenofibrate dose was increased at the end of each cycle if hypertriglyceridemia persisted and adverse effects were not documented. Complete blood count, biochemistry, and urine protein:creatinine ratio were collected serially. Baseline (T0) parameters were compared to time of maximal reduction in serum triglyceride concentrations (T1) and reported as median (range).ResultsTriglycerides normalized in all dogs (T0=662 mg/dL [189-2391]; T1= 113 mg/dL [81-132]; P=.002). Fenofibrate dose at T1=6.4mg/kg PO q24h (range, 2.2-13.5). T1 was achieved at 3 (n=4), 6 (n=4), and 9 (n=2) weeks. Serum cholesterol concentrations decreased in 9 of 10 dogs. Quiet demeanor and firm stools in 1 dog were the only reported adverse reactions. Fenofibrate administration resulted in a significant reduction in median alkaline phosphatase activity (P=.049).Conclusions and clinical importanceOver 21 to 63 days, TriCor was effective in the management of primary and secondary hyperlipidemia in dogs. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0891-6640 1939-1676 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0944a1eb223ede64ec27ab93be0fd8dTest https://doaj.org/article/8d6d251daa1d46b5a914ff55b7972198Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e0944a1eb223ede64ec27ab93be0fd8d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 08916640 19391676 |
|---|